Related Experiment Video

Updated: May 24, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis

Parviz Ahmad-Nejad1, Carl-Erik Dempfle, Christel Weiss

  • 1Institute for Clinical Chemistry, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany.

Thrombosis Research
|March 17, 2012
PubMed
Abstract

Insights

The FSAP Marburg I polymorphism is linked to an increased risk of deep vein thrombosis and recurrent blood clots. Genotyping this variant can help assess thrombophilia risk in patients with a history of VTE.

Area of Science:

  • Genetics
  • Hematology
  • Thrombosis Research

Background:

  • The Factor VII Activating Protease (FSAP) Marburg I (rs7080536) polymorphism's role in venous thrombosis has been debated due to limited data.
  • This study investigates the FSAP Marburg I polymorphism (FSAP-MI) alongside Factor V Leiden and Factor II G20210A variations.

Purpose of the Study:

  • To determine the impact of the FSAP Marburg I polymorphism on the development of venous thromboembolic disease (VTE).
  • To evaluate FSAP-MI's association with VTE in comparison to other known genetic risk factors.

Main Methods:

  • A case-control study involving 891 patients with a history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE).
  • Comparison group comprised 1283 healthy blood donors without a history of VTE.
  • Genotyping for FSAP Marburg I, Factor V Leiden, and Factor II G20210A polymorphisms.

Main Results:

  • The FSAP Marburg I (FSAP-MI) polymorphism was significantly associated with the development of DVTs (OR 1.65, 95% CI 1.16-2.34).
  • FSAP-MI was also significantly associated with recurrent thromboembolic events (DVT and PE) (OR 2.13, 95% CI 1.35-3.36).
  • Even when considering patients with one or more events, FSAP-MI remained associated with recurrent events (OR 1.64, 95% CI 1-2.69).

Conclusions:

  • FSAP Marburg-I genotyping is a valuable tool for assessing the risk of thromboembolic disorders.
  • This genotyping can aid in managing patients with suspected thrombophilia and a history of DVT or PE.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...